Clinical Trial Update: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of romidepsin and lenalidomide in previously untreated peripheral T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Non-hodgkin Lymphoma
• Mycosis Fungoides Sezary Syndrome
• Nasal Type Extranodal Nk T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Romidepsin (romidepsin)

Snippet

Sponsor: Northwestern University | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Status: UNKNOWN | Results posted: 2024-04-10